Clinical trial · Interventional
Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma
UARK 98-003, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Multiple Myeloma
NCT00083577CI-TRIAL-00003631completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research is to study how helpful thalidomide is in controlling the myeloma disease and to study any side effect resulting from thalidomide.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Thalidomide | Drug | Thalidomide | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To determine tumor response, overall and progression free survival following thalidomide therapy in patients with multiple myeloma
Secondary outcomes (1)
- measure
- To determine toxicities associated with thalidomide in patients with multiple myeloma
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All patients must have a confirmed diagnosis of previously treated, active multiple myeloma * Myeloma protein should be evident from which to evaluate response * Must be 18 years of age or older. Women of childbearing age and fertile men must use a medically acceptable means of birth control while on study and for 6 months thereafter. * Patients must sign an informed consent to participate in this study, and be fully aware of the known teratogenic potential of this drug * Patients must have a total white blood cell count of 2,000 K/microliters. Patients may be anemic or thrombocytopenic provided this is felt to be due to extensive marrow involvement with myeloma * Patients must have adequate liver function as demonstrated by a direct bilirubin of \< or = 2.0 mg/dL. Exclusion Criteria: * Patients must not have an active infection requiring parenteral antibiotics * No other concurrent therapy for myeloma is permitted while on Thalidomide
References
Publications (0)
Data not yet available
No reference posted for this study.